List view / Grid view
The medicines regulator will aim to take a more flexible…
The medicines regulator will aim to take a more flexible licensing approach for the research and manufacture of rare disease therapies in the UK.
MHRA’s publication is intended to support European developers of phage-based…
MHRA’s publication is intended to support European developers of phage-based medicinal products to effectively navigate related regulations.
The new draft guidance for personalised cancer therapies addresses the…
The new draft guidance for personalised cancer therapies addresses the questions that this new regulatory pathway creates, according to the MHRA’s Chief Executive.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has…
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a world-first regulatory authorisation to a medicine based on Nobel Prize-winning technology.
